Luis F Callado

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2366218/publications.pdf

Version: 2024-02-01

109321 128289 4,400 145 35 60 citations h-index g-index papers 161 161 161 5329 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	NRN1 Gene as a Potential Marker of Early-Onset Schizophrenia: Evidence from Genetic and Neuroimaging Approaches. International Journal of Molecular Sciences, 2022, 23, 7456.	4.1	2
2	5-HT _{2A} receptor-mediated Gî± _{q/11} activation in psychiatric disorders: A postmortem study. World Journal of Biological Psychiatry, 2021, 22, 505-515.	2.6	8
3	Di-aryl guanidinium derivatives: Towards improved α2-Adrenergic affinity and antagonist activity. European Journal of Medicinal Chemistry, 2021, 209, 112947.	5.5	4
4	Sexâ€dependent pharmacological profiles of the synthetic cannabinoid MMBâ€Fubinaca. Addiction Biology, 2021, 26, e12940.	2.6	1
5	Decreased striatal adenosine A2A-dopamine D2 receptor heteromerization in schizophrenia. Neuropsychopharmacology, 2021, 46, 665-672.	5.4	24
6	Spinophilin expression in postmortem prefrontal cortex of schizophrenic subjects: Effects of antipsychotic treatment. European Neuropsychopharmacology, 2021, 42, 12-21.	0.7	2
7	In Vivo Brain Microdialysis of Monoamines. Neuromethods, 2021, , 489-512.	0.3	O
8	5-HT2A receptor- and M1 muscarinic acetylcholine receptor-mediated activation of $Gl\pm q/11$ in postmortem dorsolateral prefrontal cortex of opiate addicts. Pharmacological Reports, 2021, 73, 1155-1163.	3.3	4
9	Subcellular specificity of cannabinoid effects in striatonigral circuits. Neuron, 2021, 109, 1513-1526.e11.	8.1	29
10	Opposite alterations of 5ÂHT2A receptor brain density in subjects with schizophrenia: relevance of radiotracers pharmacological profile. Translational Psychiatry, 2021, 11, 302.	4.8	8
11	Characterization of Hevin (SPARCL1) Immunoreactivity in Postmortem Human Brain Homogenates. Neuroscience, 2021, 467, 91-109.	2.3	3
12	Characterization of dopamine D2 receptor coupling to G proteins in postmortem brain of subjects with schizophrenia. Pharmacological Reports, 2021, 73, 1136-1146.	3.3	3
13	Benzofuranyl-2-imidazoles as imidazoline I2 receptor ligands for Alzheimer's disease. European Journal of Medicinal Chemistry, 2021, 222, 113540.	5.5	15
14	$\hat{l}\pm 2A$ - and $\hat{l}\pm 2C$ -adrenoceptor expression and functionality in postmortem prefrontal cortex of schizophrenia subjects. European Neuropsychopharmacology, 2021, 52, 3-11.	0.7	7
15	Differential brain ADRA2A and ADRA2C gene expression and epigenetic regulation in schizophrenia. Effect of antipsychotic drug treatment. Translational Psychiatry, 2021, 11, 643.	4.8	10
16	Functional coupling of M1 muscarinic acetylcholine receptor to \widehat{Gl} +q/11 in dorsolateral prefrontal cortex from patients with psychiatric disorders: a postmortem study. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 869-880.	3.2	8
17	Fundamental features of receptor-mediated $\hat{Gl\pm i}/o$ activation in human prefrontal cortical membranes: A postmortem study. Brain Research, 2020, 1747, 147032.	2.2	O
18	Bicyclic α-Iminophosphonates as High Affinity Imidazoline I ₂ Receptor Ligands for Alzheimer's Disease. Journal of Medicinal Chemistry, 2020, 63, 3610-3633.	6.4	17

#	Article	IF	Citations
19	Calcium-binding proteins are altered in the cerebellum in schizophrenia. PLoS ONE, 2020, 15, e0230400.	2.5	16
20	Long-term hippocampal interneuronopathy drives sex-dimorphic spatial memory impairment induced by prenatal THC exposure. Neuropsychopharmacology, 2020, 45, 877-886.	5.4	51
21	Ribosomal Protein S6 Hypofunction in Postmortem Human Brain Links mTORC1-Dependent Signaling and Schizophrenia. Frontiers in Pharmacology, 2020, 11, 344.	3.5	17
22	Endocannabinoid system imbalance in the postmortem prefrontal cortex of subjects with schizophrenia. Journal of Psychopharmacology, 2019, 33, 1132-1140.	4.0	21
23	Cartography of hevin-expressing cells in the adult brain reveals prominent expression in astrocytes and parvalbumin neurons. Brain Structure and Function, 2019, 224, 1219-1244.	2.3	20
24	Sudden cardiac death associated to substances of abuse and psychotropic drugs consumed by young people: A population study based on forensic autopsies. Drug and Alcohol Dependence, 2019, 201, 23-28.	3.2	17
25	Serotonin 5-HT2A receptor expression and functionality in postmortem frontal cortex of subjects with schizophrenia: Selective biased agonism via Gl̃±i1-proteins. European Neuropsychopharmacology, 2019, 29, 1453-1463.	0.7	32
26	Behavioral and Cognitive Improvement Induced by Novel Imidazoline I2 Receptor Ligands in Female SAMP8 Mice. Neurotherapeutics, 2019, 16, 416-431.	4.4	22
27	Optimization and pharmacological characterization of receptorâ€mediated G i/o activation in postmortem human prefrontal cortex. Basic and Clinical Pharmacology and Toxicology, 2019, 124, 649-659.	2.5	4
28	Differential î± _{2A} - and î± _{2C} -adrenoceptor protein expression in presynaptic and postsynaptic density fractions of postmortem human prefrontal cortex. Journal of Psychopharmacology, 2019, 33, 244-249.	4.0	10
29	A New Family of Imidazoline I 2 Receptor Ligands Improves Behavior and Cognition in SAMP8 Mice. FASEB Journal, 2019, 33, 806.19.	0.5	0
30	The role of toxic substances in sudden cardiac death. Spanish Journal of Legal Medicine, 2018, 44, 13-21.	0.2	7
31	Functional coupling between adenosine A1 receptors and G-proteins in rat and postmortem human brain membranes determined with conventional guanosine-5′-O-(3-[35S]thio)triphosphate ([35S]GTPγS) binding or [35S]GTPγS/immunoprecipitation assay. Purinergic Signalling, 2018, 14, 177-190.	2.2	2
32	Characterisation of spinophilin immunoreactivity in postmortem human brain homogenates. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 81, 236-242.	4.8	4
33	Intracellular inflammatory and antioxidant pathways in postmortem frontal cortex of subjects with major depression: effect of antidepressants. Journal of Neuroinflammation, 2018, 15, 251.	7.2	60
34	The Loss of \hat{l}_{\pm} - and \hat{l}^2 -Tubulin Proteins Are a Pathological Hallmark of Chronic Alcohol Consumption and Natural Brain Ageing. Brain Sciences, 2018, 8, 175.	2.3	15
35	The endocannabinoid system in mental disorders: Evidence from human brain studies. Biochemical Pharmacology, 2018, 157, 97-107.	4.4	53
36	Chronic cannabis promotes pro-hallucinogenic signaling of 5-HT2A receptors through Akt/mTOR pathway. Neuropsychopharmacology, 2018, 43, 2028-2035.	5.4	59

#	Article	IF	CITATIONS
37	Histamine H ₃ receptor-mediated G-protein activation in postmortem human prefrontal cortical membranes. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO1-1-132.	0.0	O
38	Novel Imidazoline I ₂ Receptor Ligands for Alzheimer's Disease. FASEB Journal, 2018, 32, 552.1.	0.5	0
39	Thiophene/thiazole-benzene replacement on guanidine derivatives targeting $\hat{l}\pm 2$ -Adrenoceptors. European Journal of Medicinal Chemistry, 2017, 138, 38-50.	5 . 5	19
40	Neuroprotective Effects of a Structurally New Family of High Affinity Imidazoline I ₂ Receptor Ligands. ACS Chemical Neuroscience, 2017, 8, 737-742.	3.5	24
41	Antipsychotic-induced Hdac2 transcription via NF-κB leads to synaptic and cognitive side effects. Nature Neuroscience, 2017, 20, 1247-1259.	14.8	79
42	Functional activation of $\widehat{Gl}\pm q$ coupled to 5-HT2A receptor and M1 muscarinic acetylcholine receptor in postmortem human cortical membranes. Journal of Neural Transmission, 2017, 124, 1123-1133.	2.8	13
43	Schizophrenia and depression, two poles of endocannabinoid system deregulation. Translational Psychiatry, 2017, 7, 1291.	4.8	38
44	Droga berriak merkatu berritzailean. Osagaiz (journal), 2017, 1, .	0.0	0
45	Group II Metabotropic Glutamate Receptors as Targets for Novel Antipsychotic Drugs. Frontiers in Pharmacology, 2016, 7, 130.	3.5	52
46	Biased Agonism of Three Different Cannabinoid Receptor Agonists in Mouse Brain Cortex. Frontiers in Pharmacology, 2016, 7, 415.	3.5	56
47	Spinophilin expression in postmortem prefrontal cortex of subjects with schizophrenia: effect of antipsychotic treatment. European Neuropsychopharmacology, 2016, 26, S571.	0.7	1
48	Alpha2C-adrenoceptor Del322-325 polymorphism and risk of psychiatric disorders: significant association with opiate abuse and dependence. World Journal of Biological Psychiatry, 2016, 17, 308-315.	2.6	7
49	Substituted conformationally restricted guanidine derivatives: Probing the α2-adrenoceptors' binding pocket. European Journal of Medicinal Chemistry, 2016, 123, 48-57.	5 . 5	15
50	Evidence of activation of the Toll-like receptor-4 proinflammatory pathway in patients with schizophrenia. Journal of Psychiatry and Neuroscience, 2016, 41, E46-E55.	2.4	65
51	The endocannabinoid system is altered in the postâ€mortem prefrontal cortex of alcoholic subjects. Addiction Biology, 2015, 20, 773-783.	2.6	34
52	α ₂ -Adrenoceptor Antagonists: Synthesis, Pharmacological Evaluation, and Molecular Modeling Investigation of Pyridinoguanidine, Pyridino-2-aminoimidazoline and Their Derivatives. Journal of Medicinal Chemistry, 2015, 58, 963-977.	6.4	26
53	Adenosine A1 receptors are selectively coupled to Gαi-3 in postmortem human brain cortex: Guanosine-5′-O-(3-[35S]thio)triphosphate ([35S]GTPγS) binding/immunoprecipitation study. European Journal of Pharmacology, 2015, 764, 592-598.	3.5	8
54	Semaphorin and plexin gene expression is altered in the prefrontal cortex of schizophrenia patients with and without auditory hallucinations. Psychiatry Research, 2015, 229, 850-857.	3.3	31

#	Article	IF	CITATIONS
55	Altered CB1 receptor coupling to G-proteins in the post-mortem caudate nucleus and cerebellum of alcoholic subjects. Journal of Psychopharmacology, 2015, 29, 1137-1145.	4.0	8
56	Alcohol-Related Brain Damage in Humans. PLoS ONE, 2014, 9, e93586.	2.5	32
57	Combining rimonabant and fentanyl in a single entity: preparation and pharmacological results. Drug Design, Development and Therapy, 2014, 8, 263.	4.3	13
58	Increased $\hat{l}\pm 2$ - and \hat{l}^21 -adrenoceptor densities in postmortem brain of subjects with depression: Differential effect of antidepressant treatment. Journal of Affective Disorders, 2014, 167, 343-350.	4.1	34
59	Evaluation of 5-HT2A and mGlu2/3 receptors in postmortem prefrontal cortex of subjects with major depressive disorder: Effect of antidepressant treatment. Neuropharmacology, 2014, 86, 311-318.	4.1	63
60	Recent cocaine use is a significant risk factor for sudden cardiovascular death in 15-49-year-old subjects: a forensic case-control study. Addiction, 2014, 109, 2071-2078.	3.3	39
61	Guanidine-based $\hat{l}\pm 2$ -adrenoceptor ligands: Towards selective antagonist activity. European Journal of Medicinal Chemistry, 2014, 82, 242-254.	5. 5	9
62	Alteraciones neurobiológicas en el alcoholismo: revisión. Revista De Psicologia De La Salud, 2014, 26, 360.	0.5	25
63	Neurobiological alterations in alcohol addiction: a review. Revista De Psicologia De La Salud, 2014, 26, 360-70.	0.5	7
64	Additive effect of rimonabant and citalopram on extracellular serotonin levels monitored with in vivo microdialysis in rat brain. European Journal of Pharmacology, 2013, 709, 13-19.	3.5	19
65	Brain RGS4 and RGS10 protein expression in schizophrenia and depression. Effect of drug treatment. Psychopharmacology, 2013, 226, 177-188.	3.1	25
66	Dysregulated 5-HT2A receptor binding in postmortem frontal cortex of schizophrenic subjects. European Neuropsychopharmacology, 2013, 23, 852-864.	0.7	71
67	Quantification of endocannabinoids in postmortem brain of schizophrenic subjects. Schizophrenia Research, 2013, 148, 145-150.	2.0	65
68	Description of a Bivalent Cannabinoid Ligand with Hypophagic Properties. Archiv Der Pharmazie, 2013, 346, 171-179.	4.1	12
69	Antidepressant-like properties of three new $\hat{l}\pm 2$ -adrenoceptor antagonists. Neuropharmacology, 2013, 65, 13-19.	4.1	22
70	Chronic Effects of Cannabinoid Drugs on Monoaminergic Systems and the Role of Endocannabinoids and Cannabinoid Receptors in Human Brain Disorders. , 2013, , 213-238.		0
71	Identification of Three Residues Essential for 5-Hydroxytryptamine 2A-Metabotropic Glutamate 2 (5-HT2A·mGlu2) Receptor Heteromerization and Its Psychoactive Behavioral Function. Journal of Biological Chemistry, 2012, 287, 44301-44319.	3.4	122
72	HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity. Nature Neuroscience, 2012, 15, 1245-1254.	14.8	247

#	Article	IF	Citations
73	A combined analysis of microarray gene expression studies of the human prefrontal cortex identifies genes implicated in schizophrenia. Journal of Psychiatric Research, 2012, 46, 1464-1474.	3.1	68
74	Neurological Soft Signs in Patients with Psychosis and Cannabis Abuse: A Systematic Review and Meta-Analysis of Paradox. Current Pharmaceutical Design, 2012, 18, 5156-5164.	1.9	30
75	Screening and quantification of antipsychotic drugs in human brain tissue by liquid chromatography–tandem mass spectrometry: Application to postmortem diagnostics of forensic interest. Forensic Science International, 2012, 219, 172-178.	2.2	41
76	The inverse agonist effect of rimonabant on G protein activation is not mediated by the cannabinoid CB1 receptor: Evidence from postmortem human brain. Biochemical Pharmacology, 2012, 83, 260-268.	4.4	27
77	Involvement of the endocannabinoid system in alcohol dependence: The biochemical, behavioral and genetic evidence. Drug and Alcohol Dependence, 2011, 117, 102-110.	3.2	22
78	Levels of Gs \hat{i} ±(short and long), G \hat{i} ±olf and G \hat{i} 2(common) subunits, and calcium-sensitive adenylyl cyclase isoforms (1, 5/6, 8) in post-mortem human brain caudate and cortical membranes: Comparison with rat brain membranes and potential stoichiometric relationships. Neurochemistry International, 2011, 58, 180-189.	3.8	2
79	Molecular adaptations of apoptotic pathways and signaling partners in the cerebral cortex of human cocaine addicts and cocaine-treated rats. Neuroscience, 2011, 196, 1-15.	2.3	48
80	P.4.006 Expression of EGR1, EGR2 and EGR3 proteins in postmortem brain of schizophrenic subjects. European Neuropsychopharmacology, 2011, 21, S82-S83.	0.7	0
81	Gliomas: Role of Monoamine Oxidase B in Diagnosis. , 2011, , 53-59.		2
82	G _i protein coupling to adenosine A ₁ –A _{2A} receptor heteromers in human brain caudate nucleus. Journal of Neurochemistry, 2010, 114, 972-980.	3.9	14
83	CocaÃna y cerebro. Trastornos Adictivos, 2010, 12, 129-134.	0.1	3
84	Opposite changes in cannabinoid CB1 and CB2 receptor expression in human gliomas. Neurochemistry International, 2010, 56, 829-833.	3.8	49
85	In vivo potentiation of reboxetine and citalopram effect on extracellular noradrenaline in rat brain by α2-adrenoceptor antagonism. European Neuropsychopharmacology, 2010, 20, 813-822.	0.7	30
86	Synthesis and pharmacological evaluation of new (E)- and (Z)-3-aryl-4-styryl-1H-pyrazoles as potential cannabinoid ligands. Arkivoc, 2010, 2010, 226-247.	0.5	12
87	Immunodensity and mRNA expression of A2A adenosine, D2 dopamine, and CB1 cannabinoid receptors in postmortem frontal cortex of subjects with schizophrenia: effect of antipsychotic treatment. Psychopharmacology, 2009, 206, 313-324.	3.1	108
88	Phosphorylation of FADD (Fas-associated death domain protein) at serine 194 is increased in the prefrontal cortex of opiate abusers: Relation to mitogen activated protein kinase, phosphoprotein enriched in astrocytes of 15 kDa, and Akt signaling pathways involved in neuroplasticity. Neuroscience, 2009, 161, 23-38.	2.3	33
89	Implicaci \tilde{A}^3 n del sistema cannabinoide end \tilde{A}^3 geno en el alcoholismo. Trastornos Adictivos, 2009, 11, 85-95.	0.1	1
90	Guanidine and 2-Aminoimidazoline Aromatic Derivatives as $\hat{1}\pm < \text{sub} > 2 < / \text{sub} > - Adrenoceptor Ligands: Searching for Structureâ^'Activity Relationships. Journal of Medicinal Chemistry, 2009, 52, 601-609.$	6.4	36

#	Article	IF	CITATIONS
91	Novel synthesis and pharmacological evaluation as $\hat{l}\pm 2$ -adrenoceptor ligands of O-phenylisouronium salts. Bioorganic and Medicinal Chemistry, 2008, 16, 8210-8217.	3.0	14
92	A follow-up investigation on the quality of medical documents from examinations of Basque incommunicado detainees. Forensic Science International, 2008, 182, 57-65.	2.2	10
93	Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature, 2008, 452, 93-97.	27.8	739
94	Guanidine and 2-Aminoimidazoline Aromatic Derivatives as $\hat{l}\pm <$ sub>2-Adrenoceptor Antagonists. 2. Exploring Alkyl Linkers for New Antidepressants. Journal of Medicinal Chemistry, 2008, 51, 3304-3312.	6.4	39
95	Monoamine oxidase B activity is increased in human gliomas. Neurochemistry International, 2008, 52, 230-234.	3.8	20
96	P.6.b.001 Study of the cannabinoid CB1 receptor funcionality in postmortem brain membranes of alcoholic subjects. European Neuropsychopharmacology, 2008, 18, S527.	0.7	0
97	Specific binding of [3H]Ro 19-6327 (lazabemide) to monoamine oxidase B is increased in frontal cortex of suicide victims after controlling for age at death. European Neuropsychopharmacology, 2008, 18, 55-61.	0.7	2
98	El sistema noradrenérgico en la neurobiologÃa de la depresión. Psiquiatria Biologica, 2008, 15, 162-174.	0.1	0
99	An Independent Meta-Analysis Using Summary Data for Clinical Response, Remission, and Discontinuation for Any Reason from the 6 Pivotal Phase III Randomized Clinical Trials of Duloxetine in Major Depressive Disorder. Journal of Clinical Psychopharmacology, 2007, 27, 219-221.	1.4	6
100	Guanidine and 2-Aminoimidazoline Aromatic Derivatives as α ₂ -Adrenoceptor Antagonists, 1:  Toward New Antidepressants with Heteroatomic Linkers. Journal of Medicinal Chemistry, 2007, 50, 4516-4527.	6.4	39
101	PMH6 ATTAINING REMISSION OF DEPRESSIVE SYMPTOMS IN THE PIVOTAL RANDOMISED CLINICAL TRIALS OF DULOXETINE IN MAJOR DEPRESSION. WHICH ARE THE MOST EFFICACIOUS DOSES?. Value in Health, 2007, 10, A288-A289.	0.3	o
102	PMH46 THE SENSITIVITYTO CHANGE OF THE HAMILTON (HAMD) AND THE MONTGOMERY-ASBERG (MADRS) SCALES AS OUTCOME MEASURES IN ANTIDEPRESSANT TRIALS. Value in Health, 2007, 10, A302.	0.3	0
103	On the search of new I2-IBS aliphatic ligands: Bis-guanidino carbonyl derivatives. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 6009-6012.	2.2	2
104	Synthesis and Pharmacological Evaluation of Chlorinated N-Alkyl-3- and -5-(2-hydroxyphenyl)pyrazoles as CB 1 Cannabinoid Ligands. Monatshefte Fýr Chemie, 2007, 138, 797-811.	1.8	14
105	Levels of G-protein $\hat{i}\pm q/11$ subunits and of phospholipase $C-\hat{i}^2(1\hat{a}\in 4)$, $-\hat{i}^3$, and $-\hat{i}'1$ isoforms in postmortem human brain caudate and cortical membranes: Potential functional implications. Neurochemistry International, 2006, 49, 72-79.	3.8	7
106	Characterization of CB1 cannabinoid receptor immunoreactivity in postmortem human brain homogenates. Neuroscience, 2006, 140, 635-643.	2.3	55
107	Synthesis and pharmacological studies of new hybrid derivatives of fentanyl active at the Î⅓-opioid receptor and I2–imidazoline binding sites. Bioorganic and Medicinal Chemistry, 2006, 14, 6570-6580.	3.0	45
108	The N251K functional polymorphism in the $\hat{l}\pm2A$ -adrenoceptor gene is not associated with depression: a study in suicide completers. Psychopharmacology, 2006, 184, 82-86.	3.1	11

#	Article	IF	Citations
109	Aminopeptidase activity in the postmortem brain of human heroin addicts. Neurochemistry International, 2005, 46, 213-219.	3.8	17
110	Subcellular distribution of membrane-bound aminopeptidases in the human and rat brain. Neuroscience Letters, 2005, 383, 136-140.	2.1	17
111	Opposite changes in Imidazoline I2 receptors and α2-adrenoceptors density in rat frontal cortex after induced gliosis. Life Sciences, 2005, 78, 205-209.	4.3	7
112	Imidazoline I2 receptor density increases with the malignancy of human gliomas. Journal of Neurology, Neurosurgery and Psychiatry, 2004, 75, 785-787.	1.9	23
113	Effectiveness of pindolol plus serotonin uptake inhibitors in depression: a meta-analysis of early and late outcomes from randomised controlled trials. Journal of Affective Disorders, 2004, 79, 137-147.	4.1	126
114	Differential Postmortem Delay Effect on Agonist-Mediated Phospholipase CÎ ² Activity in Human Cortical Crude and Synaptosomal Brain Membranes. Neurochemical Research, 2004, 29, 1461-1465.	3.3	8
115	Fentanyl Derivatives Bearing Aliphatic Alkaneguanidinium Moieties: A New Series of Hybrid Molecules with Significant Binding Affinity for μ-Opioid Receptors and I2-Imidazoline Binding Sites ChemInform, 2004, 35, no.	0.0	0
116	Fentanyl derivatives bearing aliphatic alkaneguanidinium moieties: a new series of hybrid molecules with significant binding affinity for $\hat{l}^1\!\!/\!\!4$ -opioid receptors and I2-imidazoline binding sites. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 491-493.	2.2	20
117	Stereoselective effects of ketamine on dopamine, serotonin and noradrenaline release and uptake in rat brain slices. Neurochemistry International, 2004, 44, 1-7.	3.8	68
118	Characterization of [3 H]idazoxan binding sites on human platelets. Platelets, 2002, 13, 241-246.	2.3	19
119	Synthesis and opioid activity of new fentanyl analogs. Life Sciences, 2002, 71, 1023-1034.	4.3	20
120	Long-Acting Fentanyl Analogues: Synthesis and Pharmacology of N-(1-Phenylpyrazolyl)-N-(1-phenylalkyl-4-piperidyl)propanamides. Bioorganic and Medicinal Chemistry, 2002, 10, 817-827.	3.0	35
121	Guanidinium and aminoimidazolinium derivatives of N-(4-piperidyl)propanamides as potential ligands for $\hat{l}^1\!\!/\!\!\!/$ opioid and I2-imidazoline receptors: synthesis and pharmacological screening. Bioorganic and Medicinal Chemistry, 2002, 10, 1009-1018.	3.0	29
122	Spatiotemporal Interaction of $\hat{l}\pm 2$ Autoreceptors and Noradrenaline Transporters in the Rat Locus Coeruleus. Journal of Neurochemistry, 2002, 74, 2350-2358.	3.9	36
123	Altered presynaptic function in monoaminergic neurons of monoamine oxidase-A knockout mice. European Journal of Neuroscience, 2002, 15, 1516-1522.	2.6	26
124	I 2 -Imidazoline Binding Site Affinity of a Structurally Different Type of Ligands. Bioorganic and Medicinal Chemistry, 2002, 10, 1525-1533.	3.0	20
125	Assessment of the Quality of Medical Documents Issued in Central Police Stations in Madrid, Spain: The Doctor's Role in the Prevention of III-Treatment. Journal of Forensic Sciences, 2002, 47, 293-298.	1.6	8
126	Regulation of phospholipase $\hat{Cl^2}$ activity by muscarinic acetylcholine and 5-HT2 receptors in crude and synaptosomal membranes from human cerebral cortex. Neuropharmacology, 2001, 40, 686-695.	4.1	25

#	Article	IF	Citations
127	Differential [3H]idazoxan and [3H]2-(2-benzofuranyl)-2-imidazoline (2-BFI) binding to imidazoline I2 receptors in human postmortem frontal cortex. European Journal of Pharmacology, 2001, 423, 109-114.	3.5	5
128	Effects of chronic tramadol on pre- and post-synaptic measures of monoamine function. Journal of Psychopharmacology, 2001, 15, 147-153.	4.0	20
129	Effects of dizocilpine (MK 801) on noradrenaline, serotonin and dopamine release and uptake. NeuroReport, 2000, 11, 173-176.	1.2	39
130	I2-Imidazoline receptors and monoamine oxidase B enzyme sites in human brain: covariation with age. Neuroscience Letters, 2000, 288, 135-138.	2.1	7
131	α2A- But not α2B/C-adrenoceptors modulate noradrenaline release in rat locus coeruleus: voltammetric data. European Journal of Pharmacology, 1999, 366, 35-39.	3.5	91
132	Differential modulation of $\hat{l}\pm 2$ -adrenoceptor subtypes in rat kidney by chronic desipramine treatment. Life Sciences, 1999, 64, 2327-2339.	4.3	3
133	Selective Increase of α _{2A} â€Adrenoceptor Agonist Binding Sites in Brains of Depressed Suicide Victims. Journal of Neurochemistry, 1998, 70, 1114-1123.	3.9	118
134	Differences in Criminal Activity Between Heroin Abusers and Subjects Without Psychiatric Disordersâ€"Analysis of 578 Detainees in Bilbao, Spain. Journal of Forensic Sciences, 1998, 43, 993-999.	1.6	17
135	Low-affinity conditions for agonists increase the binding of the antagonist []RX821002 to the $\hat{l}\pm2B/C$ -adrenoceptor subtypes in human brain and rat kidney. European Journal of Pharmacology, 1997, 332, 109-112.	3 . 5	6
136	The Density of Monoamine Oxidase B Sites Is Not Altered in the Postmortem Brain of Alcoholics. Alcoholism: Clinical and Experimental Research, 1997, 21, 1479-1483.	2.4	4
137	Alleged police ill-treatment of non-political detainees in the Basque Country (Spain). Prevalence and associated factors. Forensic Science International, 1997, 87, 125-136.	2.2	2
138	α2-Adrenoceptor subtypes in the human brain: a pharmacological delineation of [3H]RX-821002 binding to membranes and tissue sections. European Journal of Pharmacology, 1996, 310, 83-93.	3 . 5	48
139	The subtype-selective α2-adrenoceptor antagonists BRL 44408 and ARC 239 also recognize 5-HT1A receptors in the rat brain. European Journal of Pharmacology, 1996, 312, 385-388.	3.5	35
140	[3H]RX821002 (2-methoxyidazoxan) binds to $\hat{l}\pm 2$ -adrenoceptor subtypes and a non-adrenoceptor imidazoline binding site in rat kidney. European Journal of Pharmacology, 1996, 316, 359-368.	3 . 5	21
141	Increased density of I2-imidazoline receptors in human glioblastomas. NeuroReport, 1996, 7, 1393-1396.	1.2	31
142	Prevalence and methods of torture claimed in the Basque Country (Spain) during 1992–1993. Forensic Science International, 1995, 76, 151-158.	2.2	5
143	Non-adrenoceptor [3H]idazoxan binding sites (I2-imidazoline sites) are increased in postmortem brain from patients with Alzheimer's disease. Neuroscience Letters, 1993, 160, 109-112.	2.1	72
144	Paziente eskizofreniko eta kontrolen garun kortexean D2, CB1 eta m $Glu2$ hartzaileen espresio aldakortasunaren ikerketa. , 0 , , .		0

ARTICLE IF CITATIONS

145 Giza garun postmortemeko nukleo neuronalen eta ez-neuronalen banaketa.,0,,.

0